Generic Alunbrig Availability
Last updated on Apr 10, 2025.
Alunbrig is a brand name of brigatinib, approved by the FDA in the following formulation(s):
ALUNBRIG (brigatinib - tablet;oral)
-
Manufacturer: TAKEDA PHARMS USA
Approval date: April 28, 2017
Strength(s): 30MG [RLD], 90MG [RLD] -
Manufacturer: TAKEDA PHARMS USA
Approval date: October 2, 2017
Strength(s): 180MG [RLD]
Is there a generic version of Alunbrig available?
No. There is currently no therapeutically equivalent version of Alunbrig available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Alunbrig. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine
Patent 10,385,078
Issued: August 20, 2019
Inventor(s): Rozamus; Leonard W. et al.
Assignee(s): ARIAD PHARMACEUTICALS, INC. (Cambridge, MA)Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein.
Patent expiration dates:
- November 10, 2035✓✓✓
- November 10, 2035
-
Phosphorous derivatives as kinase inhibitors
Patent 9,012,462
Issued: April 21, 2015
Inventor(s): Wang Yihan & Huang Wei-Sheng & Liu Shuangying & Shakespeare William C. & Thomas R. Mathew & Qi Jiwei & Li Feng & Zhu Xiaotian & Kohlman Anna & Dalgarno David C. & Romero Jan Antoinette C. & Zou Dong
Assignee(s): Ariad Pharmaceuticals, Inc.The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.
Patent expiration dates:
- April 28, 2031✓
- April 28, 2031
-
Phosphorus derivatives as kinase inhibitors
Patent 9,273,077
Issued: March 1, 2016
Inventor(s): Wang Yihan & Huang Wei-Sheng & Liu Shuangying & Shakespeare William C. & Thomas R. Mathew & Qi Jiwei & Li Feng & Zhu Xiaotian & Kohlmann Anna & Dalgarno David C. & Romero Jan Antoinette C. & Zou Dong
Assignee(s): ARIAD Pharmaceuticals, Inc.The invention features compounds of the general formula:
Patent expiration dates:
- May 21, 2029✓
- May 21, 2029
-
Methods for inhibiting cell proliferation in ALK-driven cancers
Patent 9,611,283
Issued: April 4, 2017
Inventor(s): Zhang Sen & Shakespeare William C. & Rivera Victor M.
Assignee(s): Ariad Pharmaceuticals, Inc.The invention features a method for treating patients who have an ALK-driven cancer, which is, or has become, refractory to one or more of crizotinib, CH5424802 and ASP3026, or which bears an ALK mutation identified herein, by administering a compound of formula (I) to the patient. The invention also features methods, kits, and compositions for characterizing ALK-driven cancers to determine whether they express an ALK mutant.
Patent expiration dates:
- April 10, 2034✓
- April 10, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 22, 2027 - FOR THE TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA-APPROVED TEST, NOT INCLUDING PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB
More about Alunbrig (brigatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
